Janssen Halts Clinical Development of Alzheimer’s Candidate Atabecestat Due to Liver Issues

Janssen Halts Clinical Development of Alzheimer’s Candidate Atabecestat Due to Liver Issues
Janssen pulled the plug on a Phase 2b/3 trial and a Phase 2 safety study of its Alzheimer’s disease experimental therapy atabecestat due to toxicity issues as a result of serious elevations in liver enzymes seen in some study participants. Atabecestat is a BACE inhibitor, intended to slow cognitive impairment. This enzyme mediates the production of beta-amyloid, which is the key component of senile plaques in the brain, and triggers cellular processes that lead to nerve cell death in Alzheimer’s disease. After reviewing all available liver safety data, the company concluded that
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *